A randomized, double-blind, placebo-controlled study of risperidone monotherapy in ambulatory bipolar disorder with concurrent moderately severe anxiety and lifetime panic or generalized anxiety disorder.
Phase of Trial: Phase III
Latest Information Update: 12 Dec 2011
At a glance
- Drugs Risperidone (Primary)
- Indications Bipolar disorders; Generalised anxiety disorder; Panic disorder
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Jun 2011 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 21 Jun 2011 Actual initiation date (Feb 2004) added as reported by ClinicalTrials.gov.